NEW YORK – Swiss firm Tecan said Tuesday that its IBL International subsidiary has formed a partnership with Grifols to develop and commercialize specialty diagnostics using a high-sensitivity, multiplexed immunoassay platform.
Under the agreement, IBL will develop biomarker panels for use with Barcelona, Spain-based Grifols' random-access, single-molecule counting (SMC) platform. The firms agreed to terms for the development, manufacturing, and commercialization of those diagnostics, including the manufacturing and supply of the panels by IBL under a master supply agreement.
Financial and other terms of the deal were not disclosed.
The companies said that the partnership will help to streamline the processes of performing low-volume, high-value tests through the development of a single workflow that can be applied to multiple specialty diagnostic parameters. They noted that Grifols' random-access technology reduces batching-related delays by offering test processing as samples arrive.
"By integrating IBL's biomarker panels with the advanced capabilities of the SMC Platform, we are enhancing clinical workflows and addressing critical gaps in patient care," Guillermo Marco-Gardoqui, senior VP of diagnostics operations and strategy at Grifols, said in a statement.
Tecan said last week that it had inked a deal to acquire from Revvity the manufacturing process for four ELISA kits, comprised of two tests that are used for specialty diagnostics and disease monitoring and two research-use-only kits.